Replies to post #141372 on Biotech Values

[vinmantoo]

acgood,

<That is exactly what they are doing though. The company is sponsoring single agent trials in both ALK lung and HER2/TN breast cancer - they definitely believe hsp90 inhibition is viable in biomarker defined populations. >

I was think more about as a single agent without genotyping the cancer, but you are correct about the single patent usage.

Based on the cash on hand, there will have to be some kind of partnership deal coming up, unless the data of the Galaxy is so compelling that the stock price surges so that the next round of financing isn't tremendously diluting.

[iwfal]

SNTA -

CFO answered a question on the call basically by saying "if we have a phase 3 ready unencumbered oncology asset, we'll have plenty of options"

I'd suggest this is naive - after watching many of these deals I suspect that companies without, say, 12 months of cash on hand get substantially poorer deals than companies with >=24 months of cash.

Anyone know of any company that had less than 12 months of cash on hand that got a good deal for a ph ii compound - (e.g. >15% royalties plus partner covers all trial costs)?